Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by neuronal loss and dysfunction of dopaminergic neurons located in the substantia nigra, which contain a variety of misfolded α-synuclein (α-syn). Medications that increase or substitute for dopamine can be used for the treatment of PD. Recently, numerous studies have shown gut microbiota plays a crucial role in regulating and maintaining multiple aspects of host physiology including host metabolism and neurodevelopment. In this review article, the role of gut microbiota in the etiological mechanism of PD will be reviewed. Furthermore, we discussed current pharmaceutical medicine-based methods to prevent and treat PD, followed by describing specific strains that affect the host brain function through the gut-brain axis. We explained in detail how gut microbiota directly produces neurotransmitters or regulate the host biosynthesis of neurotransmitters. The neurotransmitters secreted by the intestinal lumen bacteria may induce epithelial cells to release molecules that, in turn, can regulate neural signaling in the enteric nervous system and subsequently control brain function and behavior through the brain-gut axis. Finally, we proved that the microbial regulation of the host neuronal system. Endogenous α-syn can be transmitted long distance and bidirectional between ENS and brain through the circulatory system which gives us a new option that the possibility of altering the community of gut microbiota in completely new medication option for treating PD.

Introduction

Parkinson’s disease (PD), also known as tremor paralysis, is a common neurological degenerative disease in the elderly, characterized by the lesions of substantia nigra and striatum (Liepelt-Scarfone et al., 2013). Tremor, muscle rigidity, bradykinesia, and unstable posture are the main clinical symptoms of this disease. PD is associated with a variety of factors, including cerebrovascular disease (Haugarvoll et al., 2005), cerebral arteriosclerosis (Kummer et al., 2019), infections (Limphaibool et al., 2019), poisoning (Taba, 2017; Li et al., 2018), trauma, medications (Höllerhage, 2019), and genetic defects (Vila and Przedborski, 2004; Manzoni and Lewis, 2013). PD is the second most common neurodegenerative condition after Alzheimer’s disease which affects patients in the world. With the acceleration of the population aging process and decrease of physical functions of senile patients, the incidence and prevalence of PD have shown an increasing trend year by year (Nussbaum and Ellis, 2003; Hirsch et al., 2016). Approximately between 4.1 million and 4.6 million people are affected by PD in 2005 totaled, and it has been estimated that number will more than double by 2030 to between 8.7 million and 9.3 million in the most populous nations (Dorsey et al., 2007; Wang et al., 2020). The majority of people who get PD are over the age of 60, the incidence of PD among people over 60 is about one percent, men are more susceptible to PD than women at a ratio of about 3:2 (De Lau and Breteler, 2006; Dorsey and Bloem, 2018; Cerri et al., 2019).

The deposition of alpha-synuclein (α-syn) in neuronal cells could contribute to the development of PD. The α-syn is the most abundant protein constituent of Lewy bodies(LBs), which are generally described as round lamellar eosinophilic cytoplasmic inclusions (Braak et al., 2003a). LBs are the hallmark pathologic features of PD. Whether LBs are cytotoxic or cytoprotective to neuronal cells remains debatable. It could potentially be toxic since the number of cortical LBs positively correlated with the severity of symptoms of dementia in PD (Hurtig et al., 2000). However, in some cases, Lewy pathology is also found but without present parkinsonism (Parkkinen et al., 2008; Adler et al., 2010; Milber et al., 2012). Some studies have also suggested that α-syn aggregates might be protective (da Costa et al., 2000; Tanaka et al., 2004), while oligomers and pre-fibrillar α-syn are the toxic species responsible for neurodegeneration (Chen et al., 2009). The excessive accumulation of a-syn can enhance its toxicity and lead to the degeneration of DA (dopamine) neurons in the substantia nigra of the midbrain in PD, and the loss of neurons is associated with motor symptoms (Dickson et al., 2009). It is also possible rather than the neuronal loss, the presynaptic terminal failure may be the more critical pathogenic factor for motor symptoms of PD (Schulz-Schaeffer, 2010). Besides motor symptoms, PD is also associated with non-motor symptoms. In the early stage of PD, non-motor symptoms such as insomnia, impairment of smell (Shah et al., 2009) as well as gastrointestinal (GI) dysfunction (nausea, abnormal salivation, constipation, prolonged intestinal transit time etc.) (Cersosimo et al., 2013; Mulak and Bonaz, 2015) can be found. The typical movement-related symptoms, such as tremor, rigidity, bradykinesia, and postural instability are reported in the second stage of PD. In the final stage, the severe psychotic symptoms such as motor disorders and neuropsychiatric disturbances which including depression (Marsh, 2013; Parashar and Udayabanu, 2017; Guo et al., 2020; Park et al., 2020), dementia (Tsuang et al., 2013) can be observed in PD patients. The interesting phenomenon is that PD patients who suffer from GI symptoms can occur several years ahead of classic motor symptoms (Chen et al., 2015). The GI dysfunction caused by gut microbiota disorder which can initiate α-syn accumulation in the enteric nerve cell, causing concurrent mucosal inflammation and oxidative stress (Chen et al., 2019). So scientists give the hypothesis that PD may begin in the gastrointestinal tract and transfer to the brain through the gut-brain axis (Hawkes et al., 2007).

It has been shown that the intestinal microbiota and its metabolites can be involved in modulating a lot of GI functions, such as intestinal permeability (Frazier et al., 2011), mucosal immune function (Simrén et al., 2013), the motility (Cani et al., 2013) and sensitivity of the intestine (Valdez-Morales et al., 2013), as well as the activity in the ENS(enteric nervous system) (Forsythe and Kunze, 2013). The microbiota and its metabolites are also likely to modulate behaviors and brain processes, including stress responsiveness (Dinan and Cryan, 2012), emotional behavior (Foster and Neufeld, 2013), pain modulation, ingestive behavior (Cryan and Dinan, 2012), and brain biochemistry (Stilling et al., 2014). Therefore, altering the community of gut microbiota through prebiotics and antibiotics or fecal transplantation can give a new approach to treat PD due to gut microbiotas play a significant role in the neuropathogenesis of CNS (central nervous system) disorders.

The Etiological Mechanism of PD

Aging is the most important risk factor for PD, and the biochemical changes caused by aging exacerbate these abnormalities in the brain of PD (Reeve et al., 2014). Dysfunction of DA neurons will cause a neuronal loss in the substantia nigra, which ultimately leads to inhibition of motor cortex neuron activation and function (Sulzer, 2007). In PD patients, motor symptoms are mainly related to the loss of DA neurons in the substantia nigra (Yamada et al., 2004). Moreover, neuropathological changes could be found in the autonomic nervous system, olfactory structures, the lower brainstem, and cerebral cortex (Dickson, 2012; Rey et al., 2016). Extrapyramidal pathology is associated with a wide range of non-motor symptoms, which is considered as an important feature of PD (Lim and Lang, 2010). It is reported that about 80% of PD patients have gastrointestinal dysfunction especially constipation (Frazzitta et al., 2019) and the GI dysfunction can occur several years before the onset of motor symptoms. Idiopathic constipation is one of the most substantial risk factors for PD (Poirier et al., 2016). For many years, people have understood that the environmental and genetic factors can cause loss of DA neurons in the substantia nigra, which has been dramatically expanded the understanding of the etiology of PD (Schapira and Jenner, 2011). Based on lots of experiment investigations, people have reached a consensus on the mechanism of cell death induced by toxins (Anselmi et al., 2018), while how the genetic defects lead to the loss of the neurons in PD is not clear. The neuronal cell death could be caused by apoptosis or autophagy. Mitochondrial dysfunction, oxidative stress, altered protein handling, and inflammatory could be involved in the neuronal cell death (Lin and Beal, 2006; Schapira and Jenner, 2011). Mitochondria play a critical role in cellular energy metabolism, mitochondrial dysfunction and LBs formation are vital to the pathogenesis of PD (Golpich et al., 2017).

As shown before, the formation of LBs is very important for the understanding of pathogenesis in PD. Lewy neurites are the elongated structures in dendritic or axonal compartments that are in the central and peripheral nervous systems (Volpicelli-Daley et al., 2014). Both LBs and Lewy neurites are mainly composed of filaments of misfolded α-syn protein (Spillantini et al., 1998; Goedert et al., 2013) The native conformation of α-syn is a soluble monomer that serves a pivotal role in synaptic transmission and enhances the transmitter release from the presynaptic vesicle (Burré, 2015). The α-syn protein is generally expressed in the CNS with a function of modifying the supply and release of DA to regulate neurotransmission in the brain (Longhena et al., 2019). The intermediate oligomeric protofibrillar form of α-syn has been suggested to be the most toxic species (Goldberg and Lansbury, 2000). Their accumulation at presynaptic terminals will affect the pivotal steps of neurotransmitter release (Bridi and Hirth, 2018). In PD patients, the progressive degeneration of DA neurons in the dense substantia nigra of the midbrain is the main pathological change of PD (Lindvall and Kokaia, 2009).

Damage in synaptic activity by α-syn microaggregation plays a key role in DA neurons degeneration (Calo et al., 2016). In healthy conditions, the correct organization of synaptic vesicle pools in a dopaminergic striatal terminal can be observed in the brain, monomer α-syn by regulating DA transporters can control preserved DA release and reuptake (Burré, 2015). In the prodromal phases of PD, high levels of α-syn microaggregate at synaptic terminals, this will alter the size of synaptic vesicle pools. The trafficking between the reserve and readily releasable pools will be impaired (Bridi and Hirth, 2018). Misfold α-syn can misregulate or redistribute proteins of the presynaptic Soluble NSF Attachment Protein Receptor (SNARE) complex, synaptic vesicles cluster, and their recycling was attenuated (Wang et al., 2014; Bellucci et al., 2017). Furthermore, α-syn overexpression reduces dopamine transporter (DAT) membrane content and reduces DA release (Vaughan and Foster, 2013). The presynaptic alterations impair neurotransmitter exocytosis and neuronal communication. Terminal loss and axonal or cell body degeneration not yet happen during this stage. In the early stages of PD, loss of neuronal connections at terminals could trigger axonal damage synaptic and axonal loss, the onset of symptoms is related to these changes (Caminiti et al., 2017). DAT binding decreased and partial Nigrosome-1 degenerated (Wang et al., 2017). Finally, in the advanced phases of PD, broad synaptic, axonal, and cell body degeneration can be detected concomitantly participate in disease progression. The degeneration of DA neurons in PD can be mediated by apoptosis. Two particular proteins have an essential function in the process of apoptosis: DRP1 promotes mitochondrial cytochrome C release, while the OPA1 inhibits cytochrome C release (Estaquier and Arnoult, 2007; Sheridan and Martin, 2010). When the balance between the two proteins is broken, a large number of cytochrome C are released, the cell death process will happen (Suen et al., 2008). Once apoptosis is activated, amoeba changes, cell membranes blister, cytoskeleton collapse, and cytoplasm condense will also happen. These will cause nuclear agglutination, chromosome agglutination or fragmentation, plasma membrane bleb and apoptotic body formation (Elmore, 2007). Apoptotic signals are transmitted to the mitochondria, causing the release of cytochrome C, which is located in the intermembrane of mitochondria, where it acts as an electron shuttle function in the respiratory chain (Li et al., 2000). Cytochrome C binds to APAF-1 and activates caspase 9, causing protein hydrolysis and eventually leading to neuronal apoptosis (Woo et al., 2003). Under normal physiological conditions, neuronal cells have a highly resistant ability to apoptosis in the late stage of mitosis. However, pathologic apoptosis can occur in nerve cells under some stimulus. In recent years, more and more researchers have realized the importance of abnormal apoptotic pathways in the pathogenesis of PD (Lama et al., 2020).

The researchers have found that α-syn not only can regulate the neurotransmission in the brain and also it can regulate the GI function. The α-syn forms and diffuse from the intestinal tract to the brain, supporting the hypothesis that PD pathogenesis may primarily function through the gut intestine, as shown in Figure 1 (Holmqvist et al., 2014). It is reported that during the early stage of PD, the internal and external innervation of the GI tract, the dorsal motor nucleus of the vagus nerve (DMV) and the ENS of the vagus nerve were affected to various degrees by the intestine, suggesting that the PD pathogenesis observed in the gut were even earlier than the substantia nigra (Braak et al., 2003b). It has been proven that an unknown neurotropic pathogen initially damaged and disrupted the innervation of the GI tract and led to Lewy pathology of the intestine. The intestinal α-syn forms (including monomers, oligomers, and fibrils) reach the DMV through vagal innervation and eventually damage the substantia nigra, which lead to the appearance of the clinical symptoms of PD (Braak et al., 2006; Recasens and Dehay, 2014; Longhena et al., 2017) (Figure 1). According to this hyperthesis, the clinical pathology of PD can be found in the following three stages. In the early stage of PD, initial pathological α-syn appears in the olfactory bulb and DMV (Braak et al., 2003a; Forsyth et al., 2011). In the second stage of PD, substantia nigra be positive for immunoreactive α-syn inclusions (Repovš and Baddeley, 2006; Rey et al., 2016). In the final stage, as LBs reach the striatum and cerebral cortex, the severe psychotic symptoms of PD can be observed. It is reported that gut-initiated pathological processes in PD not only can be caused by a PD pathogen or environmental toxin, it also can be directly caused by gut microbiota disorder. Holmqvist proved that α-syn could be retrogradely transported from the intestinal wall to the brain by the experiment that the injection of α-syn into the intestinal wall of rats and track the transfer route (Holmqvist et al., 2014). Some researchers also found that α-syn can be transmitted via endocytosis to neighboring neurons by using in vitro and in vivo experiments (Hansen et al., 2011; Angot et al., 2012; Kim et al., 2019).

Figure 1

Since α-syn can be transmitted between brain and intestine which gives us a new option that we can modify the gut microbiota to alter the system of the intestine and reduce concurrent mucosal inflammation, eventually reduce the symptoms of PD. Nowadays, it is clear that certain bacteria are strain-specific that they can produce different essential neurotransmitters and specific neuromodulators. It is reported that several neurotransmitters such as gamma-aminobutyric acid (GABA), noradrenaline, serotonin, dopamine, and acetylcholine are produced by gut microbiota in human beings. For example, researchers reported that Lactobacillus spp., Bifidobacterium spp. (Y2) and Streptococcus salivarius subsp. thermophilus can produce GABA (Barrett et al., 2012; Pokusaeva et al., 2017). Escherichia spp., Saccharomyces spp., and Bacillus spp. can produce noradrenaline (Shishov et al., 2009; Rogers et al., 2016); Streptococcus pp., Candida spp., Enterococcus spp., and Escherichia spp. produce serotonin (Özoğul, 2004; Shishov et al., 2009; Özoğul et al., 2012); Bacillus spp.(Bacillus cereus, Bacillus mycoides, Bacillus subtilis), Escherichia coli (K-12), Hafnia alvei (NCIMB, 11999), Klebsiella pneumoniae (NCIMB, 673), Morganella morganii (NCIMB, 10466), Proteus vulgaris, Serratia marcescens, and Staphylococcus aureus can produce dopamine (Özoğul, 2004; Shishov et al., 2009; Rogers et al., 2016); and Lactobacillus spp. produce acetylcholine (Rogers et al., 2016). The neurotransmitters secreted by the intestinal lumen bacteria may induce epithelial cells to release molecules that, in turn, can regulate neural signaling in the ENS and subsequently control brain function and behavior through the brain-gut axis. In some animal studies, various bacterial strains also mediate behavioral effects through the vagus nerve (Reid, 2019). Other important molecules produced in the colon by microbial fermentation of dietary fiber are short-chain fatty acids (SCFAs), such as butyrate, acetate, and propionate. SCFAs can regulate intestinal inflammation and immune function; they can be detected in the blood circulation system and also across the blood-brain barrier (BBB) via monocarboxylate transporters to affect the CNS system. SCFAs can promote microglia-mediated neuroinflammation (Sampson et al., 2016). For example, the administration of high doses of propionate in rats can cause neurasthenia (den Besten et al., 2013). Therefore, intestinal microorganisms and their products play important roles in improving the symptoms and pathogenesis of PD.

The Current Treatments for PD

Current treatments for PD either increase/replace DA, or prevent the breakdown of DA, or prolong the action of levodopa to help control tremors (Isaacson and Hauser, 2009). Medications and surgery have been used to treat PD, but both have moderate side effects and often produce disappointing results. We will cover the current treatments related to PD and also discuss the side effects of different treatments (Table 1).

Medications Increase or Substitute for Dopamine

Since DA cannot enter into the brain, it cannot be given directly to treat PD. Medications increase or substitute for DA can be used to treat the PD.

Carbidopa-Levodopa

Levodopa can pass into the brain and be converted to DA to treat PD (Haddad et al., 2018) and carbidopa can prevent levodopa breakdown. Side effects may happen, including lightheadedness (orthostatic hypotension) (Lau et al., 2018) or nausea (Kell et al., 2017). As the disease progresses after years, the effect of levodopa becomes less stable, and a tendency to wane and dyskinesia may appear in PD (Tran et al., 2018).

Duopa Therapy

Duopa is a form of carbidopa/levodopa delivered in gel form. It delivers the medication directly to the small intestine in the gel form through a feeding tube (LeWitt, 2016). A pump slowly and consistently delivers Duopa to the intestine through the tube. This procedure allows the medicine to be absorbed smoothly and reduces motion fluctuations and movement disorders (Chaudhuri et al., 2016). The Duopa therapy has the risks that the tube may fall out or infections may happen at the infusion site or a blockage occurring in the tube.

Dopamine Agonists

DA agonists mimic DA effects in the brain, the effective time is longer than levodopa (Grall-Bronnec et al., 2018). Short-acting injectable DA agonists such as Requip, Mirapex, and Neupro can be used for quick relief in PD treatment (Pahwa and Lyons, 2009; Kulisevsky and Pagonabarraga, 2010; Yu and Fernandez, 2017). Apomorphine is a DA agonist that can be delivered by intermittent subcutaneous injections to treat the fluctuations in motor symptoms of PD (Antonini and Nitu, 2018). Side effects including hallucinations, sleepiness, and compulsive behaviors can be found (Patel et al, 2017).

MAO B Inhibitors

The brain enzyme monoamine oxidase B (MAO B) metabolizes the brain DA (Tabakman et al., 2004). MAO B inhibitors can prevent the breakdown of brain DA by inhibiting MAO B enzyme activities (Finberg, 2019). These MAO B inhibitors include rasagiline, safinamide, and selegiline (Deshwal et al., 2017; Dezsi and Vecsei, 2017; Binde et al., 2018; Szökő et al., 2018). Side effects including nausea or insomnia may happen (Dezsi and Vecsei, 2017).

Catechol O-methyltransferase (COMT) Inhibitors

COMT inhibitors mildly prolong the effect of levodopa by blocking an enzyme that can break down DA (Schlesinger and Korczyn, 2016; Katsaiti and Nixon, 2018). The medication from this class mainly includes Comtan and Tasmar (Olanow and Watkins, 2007; Lees, 2008). This medicine has a risk of serious liver damage and liver failure, other side effects include diarrhea or increased risk of dyskinesia (Silva et al., 2020).

Anticholinergics

Anticholinergics including Cogentin and trihexyphenidyl were used to control the tremor associated with PD (Olanow et al., 2001; Nishtala et al., 2016; Mishima et al., 2018). It is reported that they work better on tremors than on other PD characteristics (Lang and Lees, 2002). They are common side effects such as impaired memory, hallucinations, confusion, constipation, dry mouth, and impaired urination (Morrow et al., 2018; Hong et al., 2019).

Amantadine

It can provide short-term relief of mild symptoms. It can be used during the later stages of PD by giving together with carbidopa-levodopa therapy to control involuntary movements (Wolf et al., 2010). Side effects of amantadine may include ankle swelling, skin purple mottling, or hallucinations (Kim et al., 2018).

Creatine

Creatine is an energy compound that exerts neuroprotective effects in animal models of PD (Duarte‐Silva et al., 2018; Marques and Wyse, 2019). It also acts as an antioxidant protected against the loss of both Nissl and tyrosine hydroxylase in the substantia nigra (Xiao et al., 2014). Weight gain is the most common side effect of creatine, impairment of renal function can also be found (Bender et al., 2008).

Surgical Procedures

Deep Brain Stimulation

DBS is offered to people with advanced PD (Lee et al., 2018). DBS stabilizes medication fluctuations, reduces or prevents dyskinesias, reduces tremors and stiffness, and improves movement slowness. In deep brain stimulation (DBS), a surgeon first implants electrodes into a specific part of the patients’ brain. Then the electrodes are connected to a generator implanted in the chest near the patient’s clavicle (Follett et al., 2010). Risks such as infections, brain hemorrhage, or stroke may happen.

Gene Therapy

A lot of PD gene therapy clinical trials aim to alter local neurotransmitters or neurotrophic factors in the basal. Although these trials show that gene therapy can be safely delivered to the brain and induce specific neuronal protein expression, the clinical results have been less encouraging (Bartus et al., 2014).

Immunotherapy

Immunotherapy targeted mainly using antibodies against misfolded α-syn (George and Brundin, 2015). Previous studies have tried to remove α-syn from extracellular space, thereby reducing the progressive deposition of α-syn aggregates throughout the brain (Masliah et al., 2005; Masliah et al., 2011). A possible side effect of immunotherapy is Th17 cell-mediated inflammatory autoimmunity involving in neurodegenerative neuritis (Reynolds et al., 2010).

Cell Transplantation

Introducing new DA cells into the brain may help replace what is lost in PD. To date, there have been cell transplantation clinical trials using autologous and nonautologous cells, including the use of the human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS) (Parmar et al., 2020). The Japanese scientists have injected dopaminergic progenitor cells directly into an area of the brain associated with neural degeneration in PD in 2018 (Normile, 2018). The main challenge has been unacceptable graft-induced dyskinesia (Piquet et al., 2012).

Microbiota-Targeted Intervention Strategies to Manage PD

Nowadays, it has been estimated that the human intestinal tract harbors a diverse and complex microbial community which plays an important role in many aspects of host physiology, including nervous system development and human neurodegenerative diseases (Thomas et al., 2017; Ceppa et al., 2020). The intestinal flora is currently considered a key regulator of a smooth two-way dialogue between the intestine and the brain (gut-brain axis). This fact provides a promising opportunity for preventing or treating neuropsychiatric conditions in PD. The relationship between gut flora and the brain can be traced back to brain development. After the fetus is born, the microorganisms obtained from the mother and the environment colonize the fetus’s intestine and play a critical role in brain development (Codagnone et al., 2019). The functions of gut microbiota include participation in the synthesis of multiple vitamins and fatty acids, and regulation of brain-derived neurotrophic factor (BDNF), synaptophysin, post-synaptic density protein 95 (PSD-95) (Sudo et al., 2004). A recent study has shown that injections of LBs from PD into the striatum of baboons or the intestine could induce the damage of the nigrostriatal pathway and the pathological changes of the ENS. No pathological damage of α-syn was detected in the vagus nerve and the DMV, suggesting that DMV may not be the pathologic transmission route of α-syn. The levels of α-syn in the blood of baboons injected were increased, which was positively correlated with the levels of α-syn in ENS. Endogenous α-syn may be transmitted long-distance and bidirectional between ENS and the brain through the circulatory system (Arotcarena et al., 2020).

It has been found in sterile animal research that the intestinal flora is necessary for the healthy development of the nervous system, and the nervous system function is challenging to mature sterile animals because of the lack of intestinal flora (Luczynski et al., 2016). It was found that compared with normal mice, the expression of BDNF in the cerebral cortex and hippocampus of sterile mice was significantly reduced (Arentsen et al., 2015). And sterile mice were more likely to show anxiety and less activity performance. After transplanting the healthy intestinal flora to sterile mice, it was showed increased activity and decreased anxiety in mice, and the 5-HT content of norepinephrine, DA, and terminal brain striatum also significantly increased (De Theije et al., 2014). The anxious behaviors and activities of SPF mice indicated that the colonization rate of the GI flora during colonization could affect the corresponding excitatory neuron cell signaling mechanism to some extent.

The Association between Gut Microbiota Alteration and PD

There are associations between the composition of gut microbiota alteration and multiple prodromal markers of PD. Several studies have proven that certain bacterial taxa can be used as biomarkers or even drug targets for PD. A study showed that gut microbiota dysbiosis was observed in the PD compared to the healthy group. OTUs include Proteus sp., Bilophila sp., and Roseburia sp., were increased with PD microbiomes and members of families Lachnospiraceae, Rikenellaceae, and Peptostreptococcaceae, as well as Butyricicoccus sp. were decreased (Scheperjans et al., 2015). Another study was supporting that compared to the healthy control, the levels of Lactobacillus, Prevotellaceae, Peptostreptococcus, and Butyricicoccus spp. are lower and the levels of Proteus and Enterobacter spp. are higher (Sampson et al., 2016). A recent clinical trial including 666 elderly subjects was done to analyze the association between PD risk factors and prodromal symptoms markers with the composition of gut microbiota. The physical activity, occupation-related solvent exposure, and constipation were associated with the α-diversity of gut microbiota, and the physical activity, gender, constipation, REM sleep behavior disorder (RBD), as well as smoking, are associated with β-diversity of gut microbiota, the age and uric acid-lowering drugs are associated with both α- and β-diversity of gut microbiota. Physical inactivity and constipation in individuals were highest common with Firmicutes-enriched enterotype, while constipation is the least common among individuals with Prevotella-enriched enterotype (Heinzel et al., 2020). Another study showed Ralstonia, Proteobacteria, Enteococcaceae concentration in the mucosa of PD patients increased. These bacteria have pro-inflammatory cytokine producing function. Anti-inflammatory bacteria including Blautia, Coprococcus, Roseburia, and Faecalibacterium in the stool samples of PD patients decreased (Keshavarzian et al., 2015) The LPS (lipopolysaccharide) biosynthesis genes were also reported significantly increased in the PD fecal samples (Keshavarzian et al., 2015). Helicobacter pylori infection is also related to trigger the pathogenesis in PD (Çamcı and Oğuz, 2016). A two-year following study showed that low counts of Bacteroides fragilis were related to worsening of motivation/activeness and Bifidobacterium was associated with hallucinations/delusions (Minato et al., 2017).

A study used the microbiome-wide association study (MWAS) in two large datasets to specify the gut microbiota alteration in PD. Cluster 1 which was composed of opportunistic pathogens including Porphyromonas, Corynebacterium, Prevotella, Porphyromonas, and Corynebacterium were increased in PD. Genera in Cluster 2 including (Oscillospira, Lachnospiraceae_UCG-004, Lachnospiraceae_ND3007_group) and (Agathobacter, Butyricicoccus, Blautia, Faecalibacterium, Lachnospira, Fusicatenibacter, Roseburia) were reduced in PD. Most increased groups belong to Ruminococcaceae and Lachnospiraceae families which are already known as SCFAs producing bacteria. Lactobacillus and Bifidobacteria increased in PD in cluster 3. The genera in cluster 3 were probiotics with carbohydrate-metabolizing and possible of becoming opportunistic pathogens and immunogenic (Wallen et al., 2020). Nishiwaki et al. use a meta-analysis method compared 223 PD patients with 137 health controls and give a conclusion that genera Akkermansia, Catabacter, and families Akkermansiaceae were elevated, while Roseburia, Faecalibacterium, and Lachnospiraceae ND3007 group were decreased in PD (Nishiwaki et al., 2020). When the dietary fibers defected, Akkermansia muciniphila can degrade the gut mucus layer and enhance enteric pathogen infection risk (Desai et al., 2016). Abundance Akkermansia can increase the permeability of intestine which exposes the intestinal neural plexus to an oxidative or toxic environment, and this may lead to α-syn fibrils aggregate in the intestine. Faecalibacterium and Roseburia decreased in PD may provoke intestinal inflammatory, these two genera are butyrate-producing bacteria and butyrate belongs to SCFAs can induce anti-inflammatory cytokines gene expression by inhibiting histone deacetylase (Sokol et al., 2008; Canani et al., 2011). Cirstea also proved the intestinal function of PD is related to gut microbiota composition and metabolism (Cirstea et al., 2020). The microbiota composition of fecal samples as well as serum metabolomics were analyzed from 197 PD patients and 103 controls. There is a higher abundance of Christensenellaceae, Desulfovibrionaceae, Bifidobacterium, Bilophila, Collinsella, Akkermansia and lower abundance of Lachnospiraceae, Roseburia, Faecalibacterium in PD. The microbiota in PD showed reduced carbohydrate fermentation and low butyrate synthesis capacity, while the proteolytic fermentation and deleterious amino acid metabolites (p-cresol and phenylacetylglutamine) production were increased. The interesting phenomenon is that butyrate-producing bacteria were negatively associated with stool firmness since butyrate can regulate intestinal serotonin biosynthesis and improve the motility of colonic (Vincent et al., 2018; Cirstea et al., 2020). The SCFAs concentrations were significantly reduced in PD fecal samples. The Bacteroidetes (phylum) and Prevotellaceae (family) were reduced, and Enterobacteriaceae increased in PD. SCFAs may induce ENS alterations and dysmotility of gastrointestinal in PD (Unger et al., 2016). From all these studies, we could conclude that the opportunistic pathogens were increased, while potential benefit bacteria were reduced: Prevotellace decreased and Enterobacteriaceae increased in PD. The microbiome changed in PD is shown in Table 2.

The interplay between α‐syn and gut microbiota attracts a lot of researchers’ interest. A previous study has already confirmed that increased expression of α‐syn in the substantia nigra can cause pathology of CNS, including motor and cognitive functions impaired (Crowley et al., 2018). Nigral overexpression of α‐syn reduced neuronal number in myenteric submucosal plexus, increased glial expression in the myenteric plexus, modulated myenteric and submucosal TH (tyrosine hydroxylase) intensity, alter gut microbiota as well as bile acid composition (O’Donovan et al., 2020). Plexus neuronal loss can affect epithelial barrier integrity, secretomotor functions and immune cell migration, which can increase the permeability of intestine and GI inflammation. Potentially beneficial bacteria Faecalibacterium prausnitzii, Prevotellaceae, and Lactobacillaceae were reduced in PD, the abundance of Enterobacteriaceae was increased. Nigral overexpression of α‐syn increased the level of fecal free bile acids. The distributions of bile acid indicate the liver synthesis increased or transporter deficiencies and reabsorption of bile acid in the small intestine also reduced. CA (cholic acid) and DCA (deoxycholic acid) have a role in cognitive decline (MahmoudianDehkordi et al., 2019). Increased DCA levels can inhibit the motility of GI. The DCA level were significant positive correlations with Ruminococcaceae and significantly negatively with Lactobacillus (O’Donovan et al., 2020). Gorecki used a Thy1-αSyn PD mice model, and found LPS can induce inflammation and alter the distribution of tight junction proteins. The mucin-degrading Verrucomicrobiae and LPS-producing Gammaproteobacteria were increased in PD patients. LPS administration leads to the increasing of intestinal permeability, motor impairment, nigral α‐syn aggregation, dopaminergic neuronal loss and reduction in striatal dopamine. So LPS-producing bacteria increasing can change the gut environment and trigger the pathogenesis of PD by α‐syn aggregation (Gorecki et al., 2019). LPS or inflammatory endotoxin modulate α‐syn amyloidogenesis by the formation of intermediate nucleating species. LPS-binding structural motif interacts with soluble monomer stabilizes the α-helical intermediates in the α-syn aggregation pathway. By saturation, transfer LPS can mediate the nucleation probe. Finally, the nucleating intermediates mediated by LPS mature into divergent fibrillary forms. LPS-induced can alter the backbone motility of α‐syn, modulate α-syn aggregation, and increase LPS-α‐syn fibril formation which is toxic in PD (Bhattacharyya et al., 2019). Thus gut microbiota plays an important role in the pathology of PD.

Microbial Regulation of Host Neuronal System

The Prevotellaceace family members are important mediators of host nutrition. They can ferment complex polysaccharides to product SCFAs and modify bile acids through dietary metabolism. (Arumugam et al., 2011). The SCFAs receptors 2 (FFAR2) and 3 (FFAR3) were found expressed in the ENS, portal nerve and sensory ganglia system. The microbiota metabolites can directly function to sensory neurons or can signal to neurons via intermediate interactions with enteroendocrine or epithelial cells and regulate the host behavior (Egerod et al., 2018). The Prevotellaceae decreased which lead to intestinal permeability increased and bacterial endotoxins exposure (Figure 1), thereby initiating or retaining excess α-syn expression in the colon and supporting its misfolding (Sarkar and Banerjee, 2019). The increased Enterobacteriaceae in PD can raise the serum LPS concentration and the relative abundance of the Enterobacter spp. is also positively correlated with the severity of posture instability and gait difficulties of PD patients (Lin et al., 2019). LPS is derived from the gram-negative bacteria cell walls and crosses the intestinal wall then enter into the bloodstream and result in intestinal epithelial barrier disruption (Guo et al., 2013). LPS in the bloodstream may induce systemic inflammation (Tufekci et al., 2011), LPS as well as inflammatory cytokines like tumor necrosis factor (TNF-α), interleukin (IL)-1β, and IL-6 can disrupt BBB and promotes α-syn misfolding (Block et al., 2007), which lead to the destruction of DA neurons in the substantia nigra (Rite et al., 2007). Thus the overgrowth of Enterobacter spp. are correlated with the progression of PD (Mulak and Bonaz, 2015; Nair et al., 2018).

The approach that gut microbial interventions can be used to treat PD is supported by the fact that the gut microbiota can directly produce neurotransmitters or regulate the host biosynthesis of neurotransmitters (Bested et al., 2013), as shown in Table 3. But what are the functions of the neurotransmitters in gut microbiota and how they function on the host neuronal system is still not clear. A recent study shows that the Bacteroides fragilis can synthesis GABA and supported the KLE1738 growth, which means the GABA may be served as the growth substrate for KLE1738 (Strandwitz et al., 2019). Another study showed the 5-HT can increase the colonization rate of Turicibacter sanguinis, suggesting the role of neurotransmitter modulate bacterial colonization in the gut (Fung et al., 2019). Almost half of the host dopamine is produced by gut microbiota and up to 60% of colonic and blood 5-HT levels are biosynthesis by gut microbiota (Yano et al., 2015). Microbiota modulates the 5-HT activates in the intestine and increase the motility of GI. Microbiota also can regulate the local 5-HT to impact the central nervous system, an increasing number of researches report that the microbiome affects the host neuronal system (Sgritta et al., 2019). In the future, the microbiota specific functions on the neurological disorders and use the microbiota as the potential medical treatment for PD are needed to assess.

Gut Microbiota Approach to Treat PD

Antibiotics

Koutzoumis et al. test broad-spectrum antibiotics function on oxidopamine injected rat PD model and found 90% of microbial richness was reduced. The level of Firmicutes was reduced, while Proteobacteria, Verrucomicrobia, Bacteroidetes, and Cyanobacteria increased. Antibiotics treatment can decrease striatum IL-1b and TNF-α levels, protect dopaminergic neuron cell loss and alleviate motor deficits in the PD rodent model (Pu et al., 2019; Koutzoumis et al., 2020).

Probiotics

Probiotics treatment has been proven to be a useful method to improve the PD. Probiotics strain bifidobacteria and lactobacilli have been reported to reverse PD conditions. The regular intake of fermented milk beverages containing the probiotic Lactobacillus casei shirota has been shown to improve the bowel movement and inhibit staphylococci growth in PD patients (Cassani et al., 2011). Probiotic bacterium Bacillus spp. can convert L-tyrosine to L-DOPA, which can supply the lost dopamine of PD (Surwase and Jadhav, 2011). Some bacteria in the gut can convert levodopa to dopamine through tyrosine decarboxylases(TDC). TDC has been identified in the genome of more than 50 Enterococcus strains, several Lactobacillus and Staphylococcus, which are potential probiotics of the small intestine (Zoetendal et al., 2012; van Kessel et al., 2019). Mediterranean diet (MeDi) which contains a large quantity of Lactobacilli is shown have effective in preventing Alzheimer’s disease, several clinical studies also show that higher MeDi adherence was associated with reduced odds for PD (Alcalay et al., 2012). A study showed that pretreatment with a probiotic mixture containing B. animalis lactis, L. rhamnosus GG, and L. acidophilus has neuroprotective effects in PD models. Possibility because of butyrate can induce the BDNF and glial cell line-derived neurotrophic factor (GDNF) upregulated, and monoamine-oxidase was inhibited in the brain. Furthermore, probiotics mixture pretreatment can reduce DA neurons loss, increase the level of DA and reduce the activity of inflammatory cells of brain (Srivastav et al., 2019).

Prebiotics

Butyrate produced from bacteria is likely an interesting candidate for PD treatment. Butyrate can induce Atg5- and PI3K/Akt/mTOR-related autophagy way to cause α-syn degradation in a pesticide-induced PD rat model. The abundance of butyrate-producing bacteria elevated in the gut can prevent intestinal barrier dysfunction and increase striatal DA levels (Qiao et al., 2020).

Fecal Microbiota Transplantation (FMT)

FMT has a 1700-year history and was proposed to treat human GI diseases (Zhang et al., 2012). Currently, there are multiple ways to modulate gut microbiota, including antibiotics, probiotics, and prebiotics. Moreover, FMT remains an effective method to restore the gut microbiota ecosystem. FMT including screening for a specific microbial population, homogenizing, filtering, and resuspending stool samples, followed by colonoscopy, enema, orogastric tube, or oral delivery in the form of capsules containing lyophilized material (Biagi et al., 2013). Besides PD, FMT has been used to treat various diseases, such as Irritable bowel syndrome (IBS), type 2 diabetes, ulcerative colitis, and neurodegenerative diseases (Glass et al., 2010). Patients with PD often suffer from changes in GI motility. For example, chronic or idiopathic constipation is often found as a co-comorbid condition in PD patients and is associated with colonic and anorectal dyskinesias (Abbott et al., 2007; Mertsalmi et al., 2017; Yu et al., 2018). Several studies have shown that FMT is beneficial for the treatment of constipation in PD and can also significantly improve the non-GI symptoms of patients with neurological diseases (Sun et al., 2018; Huang et al., 2019). The discovery of the gut microbiota regulatory mechanism of PD pathogenesis has been highly valued (Borody and Khoruts, 2012; Cryan and Dinan, 2012). The proposed approach to evaluate FMT as a potential treatment for PD is primarily to assess direct communication of the vagus nerve, changes in neurotransmitter metabolites, activation of immune responses, and production of neuroactive metabolites as well as neurotoxins (Aroniadis and Brandt, 2013). A recent study using a PD mouse model as a recipient found that fecal transplantation from PD patients exacerbates dyskinesias and is associated with a decrease in Lachnospiraceae and Ruminococceae, which is a genus significantly reduced from PD patients’ stool samples (Keshavarzian et al., 2015). Besides, compared with healthy controls, FMT from PD patients may exacerbate α-syn-related motor dysfunction in α-syn overexpressing mice (Sampson et al., 2016). When transferring the gut microbiota from PD mice to normal mice, striatal neurotransmitter decreasing and motor impairment can be observed in normal mice. In fecal samples of PD, several changes can be observed: fecal SCFAs concentrations were significantly increased, the number of bacteria Proteobacteria, Turicibacterales and Enterobacteriales increased, while Firmicutes and Clostridiales decreased. FMT can suppress the TLR4/TNF-α signaling pathway which is involved in inflammation of the gut and brain. Finally, FMT administration can improve the gut dysbiosis, decrease fecal SCFAs concentration, increase DA and 5-HT levels, reduce activation of microglia and astrocytes in the substantia nigra, restore motor impairment of PD (Sun et al., 2018). Several clinical cases of PD have shown that FMT treatment can reduce symptoms of co-morbid GI, including bowel disorders, constipation, and ulcerative colitis. Compared to the traditional PD treatment methods mentioned in table 1, FMT has fewer side effects. In future, FMT treatment may also help relieve several non-GI comorbid disorders and provide additional support for the association between gut microbiota and PD. Possible microbiota-targeted intervention strategies can improve health status and prevent PD in the near future.

Conclusion

The most possible conclusion about the connection between gut microbiota and PD is that: The GI dysfunction could be found in the early stage of PD, α-syn was found in both the gut and brain. The gut disorder exacerbates α-syn deposition and will aggravate neurodegeneration. α-syn deposition may start in the ENS of PD, then accumulate and transfer to the CNS via a trans-synaptic cell-to-cell transmission (Lionnet et al., 2018). The imbalance of the gut tract shows a pro-inflammatory environment, the number of the pathogen was elevated, the permeability of the intestinal epithelial barrier also increased. The inflammatory signals could be transferred to the brain through the gut-brain axis and cause brain & behavior dysfunction.

Gut microbiota has been shown as the potential modulator of human health. They play an important role in the intestine system and brain function. Current studies indicate that modify gut microbiota composition can affect brain neurochemistry via neural, immune and endocrine. Through antibiotics, probiotics, prebiotics or FMT approach could restore the gut ecosystem and improve brain functions. In the future, more new GI biomarkers need to discovery and the mechanism of specific bacteria through which pathway effect on the host system needs to be clarified.

Funding

This research was financially supported by the National Natural Science Foundation of China (81773616), Shanghai Excellent Technology Leader Program (17XD1423200), Shanghai Education Development Project: Industry-University-Research Practice (A3-2601-20-311001-11), and the Natural Science Foundation of Shanghai (20ZR1424600).

References

• 1

  AbbottR. D.RossG. W.PetrovitchH.TannerC. M.DavisD. G.MasakiK. H.et al. (2007). Bowel movement frequency in late-life and incidental Lewy bodies. Mov. Disord.22, 1581–1586. doi: 10.1002/mds.21560

  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  AdlerC. H.ConnorD. J.HentzJ. G.SabbaghM. N.CavinessJ. N.ShillH. A.et al. (2010). Incidental Lewy body disease: clinical comparison to a control cohort. Mov. Disord.25, 642–646. doi: 10.1002/mds.22971

  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  AlcalayR. N.GuY.Mejia-SantanaH.CoteL.MarderK. S.ScarmeasN. (2012). The association between Mediterranean diet adherence and Parkinson’s disease. Mov. Disord.27, 771–774. doi: 10.1002/mds.24918

  • CrossRef
  • Google Scholar
  • View reference in article

• 4

  AngotE.SteinerJ. A.ToméC. M. L.EkströmP.MattssonB.BjörklundA.et al. (2012). Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One7, e39465. doi: 10.1371/journal.pone.0039465

  • CrossRef
  • Google Scholar
  • View reference in article

• 5

  AnselmiL.BoveC.ColemanF.LeK.SubramanianM.VenkiteswaranK.et al. (2018). Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat. NPJ Parkinson’s Dis.4, 1–10. doi: 10.1038/s41531-018-0066-0

  • CrossRef
  • Google Scholar
  • View reference in article

• 6

  AntoniniA.NituB. (2018). Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J. Neural Transm.125, 1131–1135. doi: 10.1007/s00702-018-1906-0

  • CrossRef
  • Google Scholar
  • View reference in article

• 7

  ArentsenT.RaithH.QianY.ForssbergH.HeijtzR. D. (2015). Host microbiota modulates development of social preference in mice. Microbial. Ecol. Health Dis.26, 29719. doi: 10.3402/mehd.v26.29719

  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  AroniadisO. C.BrandtL. J. (2013). Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol.29, 79–84. doi: 10.1097/MOG.0b013e32835a4b3e

  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  ArotcarenaM. L.DoveroS.PrigentA.BourdenxM.CamusS.PorrasG.et al. (2020). Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain143, 1462–1475. doi: 10.1093/brain/awaa096

  • CrossRef
  • Google Scholar
  • View reference in article

• 10

  ArumugamM.RaesJ.PelletierE.Le PaslierD.YamadaT.MendeD. R.et al. (2011). Enterotypes of the human gut microbiome. Nature473, 174–180. doi: 10.1038/nature09944

  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  BarrettE.RossR.O’tooleP.FitzgeraldG.StantonC. (2012). γ-Aminobutyric acid production by culturable bacteria from the human intestine. J. Appl. Microbiol.113, 411–417. doi: 10.1111/j.1365-2672.2012.05344.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  BartusR. T.WeinbergM. S.SamulskiR. J. (2014). Parkinson’s disease gene therapy: success by design meets failure by efficacy. Mol. Ther.22, 487–497. doi: 10.1038/mt.2013.281

  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  BellucciA.AntoniniA.PizziM.SpanoP. (2017). The end is the beginning: Parkinson’s disease in the light of brain imaging. Front. Aging Neurosci.9, 330. doi: 10.3389/fnagi.2017.00330

  • CrossRef
  • Google Scholar
  • View reference in article

• 14

  BenderA.SamtlebenW.ElstnerM.KlopstockT. (2008). Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutr. Res.28, 172–178. doi: 10.1016/j.nutres.2008.01.001

  • CrossRef
  • Google Scholar
  • View reference in article

• 15

  BestedA. C.LoganA. C.SelhubE. M. (2013). Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: Part I–autointoxication revisited. Gut Pathog.5, 5. doi: 10.1186/1757-4749-5-5

  • CrossRef
  • Google Scholar
  • View reference in article

• 16

  BhattacharyyaD.MohiteG. M.KrishnamoorthyJ.GayenN.MehraS.NavalkarA.et al. (2019). Lipopolysaccharide from gut microbiota modulates α-synuclein aggregation and alters its biological function. ACS Chem. Neurosci.10, 2229–2236. doi: 10.1021/acschemneuro.8b00733

  • CrossRef
  • Google Scholar
  • View reference in article

• 17

  BiagiE.CandelaM.TurroniS.GaragnaniP.FranceschiC.BrigidiP. (2013). Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol. Res.69, 11–20. doi: 10.1016/j.phrs.2012.10.005

  • CrossRef
  • Google Scholar
  • View reference in article

• 18

  BindeC. D.TveteI. F.GåsemyrJ.NatvigB.KlempM. (2018). A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson’s disease. Br. J. Clin. Pharmacol.84, 1917–1927. doi: 10.1111/bcp.13651

  • CrossRef
  • Google Scholar
  • View reference in article

• 19

  BlockM. L.ZeccaL.HongJ.-S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci.8, 57–69. doi: 10.1038/nrn2038

  • CrossRef
  • Google Scholar
  • View reference in article

• 20

  BorodyT. J.KhorutsA. (2012). Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol.9, 88. doi: 10.1038/nrgastro.2011.244

  • CrossRef
  • Google Scholar
  • View reference in article

• 21

  BraakH.Del TrediciK.RübU.De VosR. A.SteurE. N. J.BraakE. (2003a). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24, 197–211. doi: 10.1016/S0197-4580(02)00065-9

  • CrossRef
  • Google Scholar
  • View reference in article

• 22

  BraakH.RübU.GaiW.Del TrediciK. (2003b). Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm.110, 517–536. doi: 10.1007/s00702-002-0808-2

  • CrossRef
  • Google Scholar
  • View reference in article

• 23

  BraakH.De VosR. A.BohlJ.Del TrediciK. (2006). Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci. Lett.396, 67–72. doi: 10.1016/j.neulet.2005.11.012

  • CrossRef
  • Google Scholar
  • View reference in article

• 24

  BridiJ. C.HirthF. (2018). Mechanisms of α-synuclein induced synaptopathy in Parkinson’s disease. Front. Neurosci.12, 80. doi: 10.3389/fnins.2018.00080

  • CrossRef
  • Google Scholar
  • View reference in article

• 25

  BurréJ. (2015). The synaptic function of α-synuclein. J. Parkinson’s Dis.5, 699–713. doi: 10.3233/JPD-150642

  • CrossRef
  • Google Scholar
  • View reference in article

• 26

  CaloL.WegrzynowiczM.Santivañez-PerezJ.Grazia SpillantiniM. (2016). Synaptic failure and α-synuclein. Mov. Disord.31, 169–177. doi: 10.1002/mds.26479

  • CrossRef
  • Google Scholar
  • View reference in article

• 27

  ÇamcıG.OğuzS. (2016). Association between Parkinson’s disease and Helicobacter pylori. J. Clin. Neurol.12, 147–150. doi: 10.3988/jcn.2016.12.2.147

  • CrossRef
  • Google Scholar
  • View reference in article

• 28

  CaminitiS. P.PresottoL.BaronciniD.GaribottoV.MorescoR. M.GianolliL.et al. (2017). Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson’s disease. NeuroImage: Clin.14, 734–740. doi: 10.1016/j.nicl.2017.03.011

  • CrossRef
  • Google Scholar
  • View reference in article

• 29

  CananiR. B.Di CostanzoM.LeoneL.PedataM.MeliR.CalignanoA. (2011). Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J. Gastroenterol.: WJG17, 1519. doi: 10.3748/wjg.v17.i12.1519

  • CrossRef
  • Google Scholar
  • View reference in article

• 30

  CaniP. D.EverardA.DuparcT. (2013). Gut microbiota, enteroendocrine functions and metabolism. Curr. Opin. Pharmacol.13, 935–940. doi: 10.1016/j.coph.2013.09.008

  • CrossRef
  • Google Scholar
  • View reference in article

• 31

  CassaniE.PriviteraG.PezzoliG.PusaniC.MadioC.IorioL.et al. (2011). Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva gastroenterologica e Dietologica57, 117–121. doi: 10.1109/IFOST.2011.6021087

  • CrossRef
  • Google Scholar
  • View reference in article

• 32

  CeppaF. A.IzzoL.SardelliL.RaimondiI.TunesiM.AlbaniD.et al. (2020). Human Gut-Microbiota Interaction in Neurodegenerative Disorders and Current Engineered Tools for Its Modeling. Front. Cell. Infect. Microbiol.10, 297–314. doi: 10.3389/fcimb.2020.00297

  • CrossRef
  • Google Scholar
  • View reference in article

• 33

  CerriS.MusL.BlandiniF. (2019). Parkinson’s Disease in Women and Men: What’s the Difference?. J. Parkinsons Dis.9 (3), 501–515. doi: 10.3233/JPD-191683

  • CrossRef
  • Google Scholar
  • View reference in article

• 34

  CersosimoM. G.RainaG. B.PecciC.PelleneA.CalandraC. R.GutiérrezC.et al. (2013). Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J. Neurol.260, 1332–1338. doi: 10.1007/s00415-012-6801-2

  • CrossRef
  • Google Scholar
  • View reference in article

• 35

  ChaudhuriK. R.QamarM. A.RajahT.LoehrerP.SauerbierA.OdinP.et al. (2016). Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future. NPJ Parkinson’s Dis.2, 1–7. doi: 10.1038/npjparkd.2016.23

  • CrossRef
  • Google Scholar
  • View reference in article

• 36

  ChenL.PeriquetM.WangX.NegroA.McleanP. J.HymanB. T.et al. (2009). Tyrosine and serine phosphorylation of α-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest.119, 3257–3265. doi: 10.1172/JCI39088

  • CrossRef
  • Google Scholar
  • View reference in article

• 37

  ChenH.ZhaoE. J.ZhangW.LuY.LiuR.HuangX.et al. (2015). Meta-analyses on prevalence of selected Parkinson’s nonmotor symptoms before and after diagnosis. Trans. Neurodegeneration4, 1. doi: 10.1186/2047-9158-4-1

  • CrossRef
  • Google Scholar
  • View reference in article

• 38

  ChenQ.-Q.HaikalC.LiW.LiJ.-Y. (2019). Gut inflammation in association with pathogenesis of Parkinson’s disease. Front. Mol. Neurosci.12, 218. doi: 10.3389/fnmol.2019.00218

  • CrossRef
  • Google Scholar
  • View reference in article

• 39

  CirsteaM. S.YuA. C.GolzE.SundvickK.KligerD.RadisavljevicN.et al. (2020). Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson’s Disease. Mov. Disord.35, 1208–1271. doi: 10.1002/mds.28052

  • CrossRef
  • Google Scholar
  • View reference in article

• 40

  CodagnoneM. G.StantonC.O’mahonyS. M.DinanT. G.CryanJ. F. (2019). Microbiota and neurodevelopmental trajectories: role of maternal and early-life nutrition. Ann. Nutr. Metab.74, 16–27. doi: 10.1159/000499144

  • CrossRef
  • Google Scholar
  • View reference in article

• 41

  CrowleyE. K.NolanY. M.SullivanA. M. (2018). Neuroprotective effects of voluntary running on cognitive dysfunction in an α-synuclein rat model of Parkinson’s disease. Neurobiol. Aging65, 60–68. doi: 10.1016/j.neurobiolaging.2018.01.011

  • CrossRef
  • Google Scholar
  • View reference in article

• 42

  CryanJ. F.DinanT. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci.13, 701–712. doi: 10.1038/nrn3346

  • CrossRef
  • Google Scholar
  • View reference in article

• 43

  da CostaC. A.AncolioK.CheclerF. (2000). Wild-type but not Parkinson’s disease-related ala-53→ Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem.275, 24065–24069. doi: 10.1074/jbc.M002413200

  • CrossRef
  • Google Scholar
  • View reference in article

• 44

  De LauL. M.BretelerM. M. (2006). Epidemiology of Parkinson’s disease. Lancet Neurol.5, 525–535. doi: 10.1016/S1474-4422(06)70471-9

  • CrossRef
  • Google Scholar
  • View reference in article

• 45

  De TheijeC. G.WopereisH.RamadanM.Van EijndthovenT.LambertJ.KnolJ.et al. (2014). Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav. Immun.37, 197–206. doi: 10.1016/j.bbi.2013.12.005

  • CrossRef
  • Google Scholar
  • View reference in article

• 46

  den BestenG.Van EunenK.GroenA. K.VenemaK.ReijngoudD.-J.BakkerB. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res.54, 2325–2340. doi: 10.1194/jlr.R036012

  • CrossRef
  • Google Scholar
  • View reference in article

• 47

  DesaiM. S.SeekatzA. M.KoropatkinN. M.KamadaN.HickeyC. A.WolterM.et al. (2016). A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell167, 1339–1353. doi: 10.1016/j.cell.2016.10.043

  • CrossRef
  • Google Scholar
  • View reference in article

• 48

  DeshwalS.Di SanteM.Di LisaF.KaludercicN. (2017). Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease. Curr. Opin. Pharmacol.33, 64–69. doi: 10.1016/j.coph.2017.04.003

  • CrossRef
  • Google Scholar
  • View reference in article

• 49

  DezsiL.VecseiL. (2017). Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol. Disorders-Drug Targets (Formerly Curr. Drug Targets-CNS Neurol. Disorders)16, 425–439. doi: 10.2174/1871527316666170124165222

  • CrossRef
  • Google Scholar
  • View reference in article

• 50

  DicksonD. W.FujishiroH.OrrC.DelledonneA.JosephsK. A.FrigerioR.et al. (2009). Neuropathology of non-motor features of Parkinson disease. Parkinsonism related Disord.15, S1–S5. doi: 10.1016/S1353-8020(09)70769-2

  • CrossRef
  • Google Scholar
  • View reference in article

• 51

  DicksonD. W. (2012). Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harbor Perspect. Med.2, a009258. doi: 10.1101/cshperspect.a009258

  • CrossRef
  • Google Scholar
  • View reference in article

• 52

  DinanT. G.CryanJ. F. (2012). Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology37, 1369–1378. doi: 10.1016/j.psyneuen.2012.03.007

  • CrossRef
  • Google Scholar
  • View reference in article

• 53

  DorseyE. R.BloemB. R. (2018). The Parkinson pandemic—a call to action. JAMA Neurol.75, 9–10. doi: 10.1001/jamaneurol.2017.3299

  • CrossRef
  • Google Scholar

• 54

  DorseyE.ConstantinescuR.ThompsonJ.BiglanK.HollowayR.KieburtzK.et al. (2007). Projected number of people with Parkinson disease in the most populous nations 2005 through 2030. Neurology68, 384–386. doi: 10.1212/01.wnl.0000247740.47667.03

  • CrossRef
  • Google Scholar

• 55

  Duarte-SilvaS.Neves-CarvalhoA.Soares-CunhaC.SilvaJ. M.Teixeira-CastroA.VieiraR.et al. (2018). Neuroprotective effects of creatine in the CMVMJD135 mouse model of spinocerebellar ataxia type 3. Mov. Disord.33, 815–826. doi: 10.1002/mds.27292

  • CrossRef
  • Google Scholar

• 56

  EgerodK. L.PetersenN.TimshelP. N.ReklingJ. C.WangY.LiuQ.et al. (2018). Profiling of G protein-coupled receptors in vagal afferents reveals novel gut-to-brain sensing mechanisms. Mol. Metab.12, 62–75. doi: 10.1016/j.molmet.2018.03.016

  • CrossRef
  • Google Scholar

• 57

  ElmoreS. (2007). Apoptosis: a review of programmed cell death. Toxicol. Pathol.35, 495–516. doi: 10.1080/01926230701320337

  • CrossRef
  • Google Scholar

• 58

  EstaquierJ.ArnoultD. (2007). Inhibiting Drp1-mediated mitochondrial fission selectively prevents the release of cytochrome c during apoptosis. Cell Death Differ.14, 1086–1094. doi: 10.1038/sj.cdd.4402107

  • CrossRef
  • Google Scholar

• 59

  FinbergJ. P. (2019). Inhibitors of MAO-B and COMT: Their effects on brain dopamine levels and uses in Parkinson’s disease. J. Neural Transm.126, 433–448. doi: 10.1007/s00702-018-1952-7

  • CrossRef
  • Google Scholar

• 60

  FollettK. A.WeaverF. M.SternM.HurK.HarrisC. L.LuoP.et al. (2010). Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N. Engl. J. Med.362, 2077–2091. doi: 10.1056/NEJMoa0907083

  • CrossRef
  • Google Scholar

• 61

  ForsythC. B.ShannonK. M.KordowerJ. H.VoigtR. M.ShaikhM.JaglinJ. A.et al. (2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One6, e28032. doi: 10.1371/journal.pone.0028032

  • CrossRef
  • Google Scholar

• 62

  ForsytheP.KunzeW. A. (2013). Voices from within: gut microbes and the CNS. Cell. Mol. Life Sci.70, 55–69. doi: 10.1007/s00018-012-1028-z

  • CrossRef
  • Google Scholar

• 63

  FosterJ. A.NeufeldK.-a. (2013). Gut–brain axis: how the microbiome influences anxiety and depression. Trends Neurosci.36, 305–312. doi: 10.1016/j.tins.2013.01.005

  • CrossRef
  • Google Scholar

• 64

  FrazierT. H.DibaiseJ. K.McclainC. J. (2011). Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. J. Parenteral Enteral Nutr.35, 14S–20S. doi: 10.1177/0148607111413772

  • CrossRef
  • Google Scholar

• 65

  FrazzittaG.FerrazzoliD.FoliniA.PalamaraG.MaestriR. (2019). Severe constipation in Parkinson’s disease and in Parkinsonisms: prevalence and affecting factors. Front. Neurol.10, 621. doi: 10.3389/fneur.2019.00621

  • CrossRef
  • Google Scholar

• 66

  FungT. C.VuongH. E.LunaC. D.PronovostG. N.AleksandrovaA. A.RileyN. G.et al. (2019). Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. Nat. Microbiol.4, 2064–2073. doi: 10.1038/s41564-019-0540-4

  • CrossRef
  • Google Scholar

• 67

  GeorgeS.BrundinP. (2015). Immunotherapy in Parkinson’s disease: micromanaging alpha-synuclein aggregation. J. Parkinson’s Dis.5, 413–424. doi: 10.3233/JPD-150630

  • CrossRef
  • Google Scholar

• 68

  GlassC. K.SaijoK.WinnerB.MarchettoM. C.GageF. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell140, 918–934. doi: 10.1016/j.cell.2010.02.016

  • CrossRef
  • Google Scholar

• 69

  GoedertM.SpillantiniM. G.Del TrediciK.BraakH. (2013). 100 years of Lewy pathology. Nat. Rev. Neurol.9, 13. doi: 10.1038/nrneurol.2012.242

  • CrossRef
  • Google Scholar

• 70

  GoldbergM. S.LansburyP. T.Jr. (2000). Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? Nat. Cell Biol.2, E115–E119. doi: 10.1038/35017124

  • CrossRef
  • Google Scholar

• 71

  GolpichM.AminiE.MohamedZ.Azman AliR.Mohamed IbrahimN.AhmadianiA. (2017). Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci. Ther.23, 5–22. doi: 10.1111/cns.12655

  • CrossRef
  • Google Scholar

• 72

  GoreckiA. M.PreskeyL.BakebergM. C.KennaJ. E.GildenhuysC.MacdougallG.et al. (2019). Altered gut microbiome in Parkinson’s disease and the influence of lipopolysaccharide in a human α-synuclein over-expressing mouse model. Front. Neurosci.13, 839. doi: 10.3389/fnins.2019.00839

  • CrossRef
  • Google Scholar

• 73

  Grall-BronnecM.Victorri-VigneauC.DonnioY.LeboucherJ.RousseletM.ThiabaudE.et al. (2018). Dopamine agonists and impulse control disorders: a complex association. Drug Saf.41, 19–75. doi: 10.1007/s40264-017-0590-6

  • CrossRef
  • Google Scholar

• 74

  GuoS.Al-SadiR.SaidH. M.MaT. Y. (2013). Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am. J. Pathol.182, 375–387. doi: 10.1016/j.ajpath.2012.10.014

  • CrossRef
  • Google Scholar

• 75

  GuoT.GuanX.ZhouC.GaoT.WuJ.SongZ.et al. (2020). Clinically relevant connectivity features define three subtypes of Parkinson’s disease patients. Hum. Brain Mapp.41, 4077–4092. doi: 10.1002/hbm.25110

  • CrossRef
  • Google Scholar

• 76

  HaddadF.SawalhaM.KhawajaY.NajjarA.KaramanR. (2018). Dopamine and levodopa prodrugs for the treatment of Parkinson’s disease. Molecules23, 40. doi: 10.3390/molecules23010040

  • CrossRef
  • Google Scholar

• 77

  HansenC.AngotE.BergströmA.-L.SteinerJ. A.PieriL.PaulG.et al. (2011). α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest.121, 715–725. doi: 10.1172/JCI43366

  • CrossRef
  • Google Scholar

• 78

  HaugarvollK.AarslandD.Wentzel-LarsenT.LarsenJ. (2005). The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson’s disease. Acta Neurol. Scand.112, 386–390. doi: 10.1111/j.1600-0404.2005.00389.x

  • CrossRef
  • Google Scholar

• 79

  HawkesC. H.Del TrediciK.BraakH. (2007). Parkinson’s disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol.33, 599–614. doi: 10.1111/j.1365-2990.2007.00874.x

  • CrossRef
  • Google Scholar

• 80

  HeinzelS.AhoV. T. E.SuenkelU.Von ThalerA. K.SchulteC.DeuschleC.et al. (2020). Gut microbiome signatures of risk and prodromal markers of Parkinson’s disease. Ann. Neurol.88, 320–331. doi: 10.1002/ana.25788

  • CrossRef
  • Google Scholar

• 81

  HirschL.JetteN.FrolkisA.SteevesT.PringsheimT. (2016). The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology46, 292–300. doi: 10.1159/000445751

  • CrossRef
  • Google Scholar

• 82

  HöllerhageM. (2019). “Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults,” in International review of neurobiology. (ElsevierAcademic Press), 377–418.

  • Google Scholar

• 83

  HolmqvistS.ChutnaO.BoussetL.Aldrin-KirkP.LiW.BjörklundT.et al. (2014). Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol128, 805–820. doi: 10.1007/s00401-014-1343-6

  • CrossRef
  • Google Scholar

• 84

  HongC.-T.ChanL.WuD.ChenW.-T.ChienL.-N. (2019). Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson’s disease. Parkinsonism Related Disord.65, 224–229. doi: 10.1016/j.parkreldis.2019.06.022

  • CrossRef
  • Google Scholar

• 85

  HuangH.XuH.LuoQ.HeJ.LiM.ChenH.et al. (2019). Fecal microbiota transplantation to treat Parkinson’s disease with constipation: A case report. Medicine98, 129. doi: 10.1097/MD.0000000000016163

  • CrossRef
  • Google Scholar

• 86

  HurtigH.TrojanowskiJ.GalvinJ.EwbankD.SchmidtM.LeeV.-Y.et al. (2000). Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease, (2001):: Treatment Guidelines. Neurology54, 1916–1921. doi: 10.1212/WNL.54.10.1916

  • CrossRef
  • Google Scholar

• 87

  IsaacsonS. H.HauserR. A. (2009). Improving symptom control in early Parkinson’s disease. Ther. Adv. Neurol. Disord.2, 393–400. doi: 10.1177/1756285609339383

  • CrossRef
  • Google Scholar

• 88

  KatsaitiI.NixonJ. (2018). Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson’s Disease Patients? A Systematic Review. J. Parkinson’s Dis.8, 217–231. doi: 10.3233/JPD-171225

  • CrossRef
  • Google Scholar

• 89

  KellS.KhannaS.RustayN.GuptaS. (2017). Adverse event reports in PD patients receiving extended-release carbidopa-levodopa: Effects of age. Innov Aging1, 865. doi: 10.1093/geroni/igx004.3113

  • CrossRef
  • Google Scholar

• 90

  KeshavarzianA.GreenS. J.EngenP. A.VoigtR. M.NaqibA.ForsythC. B.et al. (2015). Colonic bacterial composition in Parkinson’s disease. Mov. Disord.30, 1351–1360. doi: 10.1002/mds.26307

  • CrossRef
  • Google Scholar

• 91

  KimA.KimY. E.YunJ. Y.KimH.-J.YangH.-J.LeeW.-W.et al. (2018). Amantadine and the risk of dyskinesia in patients with early Parkinson’s disease: an open-label, pragmatic trial. J. Mov. Disord.11, 65. doi: 10.14802/jmd.18005

  • CrossRef
  • Google Scholar

• 92

  KimS.KwonS.-H.KamT.-I.PanickerN.KaruppagounderS. S.LeeS.et al. (2019). Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron103, 627–641. e627. doi: 10.1016/j.neuron.2019.05.035

  • CrossRef
  • Google Scholar

• 93

  KoutzoumisD. N.VergaraM.PinoJ.BuddendorffJ.KhoshboueiH.MandelR. J.et al. (2020). Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson’s disease. Exp. Neurol.325, 113159. doi: 10.1016/j.expneurol.2019.113159

  • CrossRef
  • Google Scholar

• 94

  KulisevskyJ.PagonabarragaJ. (2010). Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease. Drug Saf.33, 147–161. doi: 10.2165/11319860-000000000-00000

  • CrossRef
  • Google Scholar

• 95

  KummerB. R.DiazI.WuX.AaroeA. E.ChenM. L.IadecolaC.et al. (2019). Associations between cerebrovascular risk factors and parkinson disease. Ann. Neurol.86, 572–581. doi: 10.1002/ana.25564

  • CrossRef
  • Google Scholar

• 96

  LamaA.PirozziC.AvaglianoC.AnnunziataC.MollicaM. P.CalignanoA.et al. (2020). Nutraceuticals: an integrative approach to starve Parkinson’s disease. Brain Behav. Immunity-Health2, 100037. doi: 10.1016/j.bbih.2020.100037

  • CrossRef
  • Google Scholar

• 97

  LangA. E.LeesA. (2002). Management of Parkinson’s disease: an evidence-based review. Mov. Disord.17, S1–S166. doi: 10.1002/mds.5554

  • CrossRef
  • Google Scholar

• 98

  LauA. C.DiggleJ. L.BringP. P. (2018). Improvement in severe orthostatic hypotension following carbidopa dose reduction. Can. J. Neurol. Sci.45, 252–253. doi: 10.1017/cjn.2017.284

  • CrossRef
  • Google Scholar

• 99

  LeeD. J.DallapiazzaR. F.De VlooP.LozanoA. M. (2018). Current surgical treatments for Parkinson’s disease and potential therapeutic targets. Neural Regener. Res.13, 1342. doi: 10.4103/1673-5374.235220

  • CrossRef
  • Google Scholar

• 100

  LeesA. J. (2008). Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson’s disease. CNS Neurosci. Ther.14, 83–93. doi: 10.1111/j.1755-5949.2007.00035.x

  • CrossRef
  • Google Scholar

• 101

  LeWittP. A. (2016). New levodopa therapeutic strategies. Parkinsonism Related Disord.22, S37–S40. doi: 10.1016/j.parkreldis.2015.09.021

  • CrossRef
  • Google Scholar

• 102

  LiJ.ChouM.LaiP. (2018). “Carbon Monoxide Poisoning-Induced Parkinsonism: A Prospective Study of Clinical and Neuroimage Correlation,” in Movement Disorders. NJ USA: Wiley, S70–S70.

  • Google Scholar

• 103

  LiK.LiY.SheltonJ. M.RichardsonJ. A.SpencerE.ChenZ. J.et al. (2000). Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis. Cell101, 389–399. doi: 10.1016/S0092-8674(00)80849-1

  • CrossRef
  • Google Scholar

• 104

  Liepelt-ScarfoneI.GaussK.MaetzlerW.MullerK.BormannC.Fruhmann BergerM.et al. (2013). Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. Neuroepidemiology41, 174–182. doi: 10.1159/000353560

  • CrossRef
  • Google Scholar

• 105

  LimS. Y.LangA. E. (2010). The nonmotor symptoms of Parkinson’s disease—an overview. Mov. Disord.25, S123–S130. doi: 10.1002/mds.22786

  • CrossRef
  • Google Scholar

• 106

  LimphaiboolN.IwanowskiP.HolstadM. J. V.KobylarekD.KozubskiW. (2019). Infectious etiologies of Parkinsonism: pathomechanisms and clinical implications. Front. Neurol.10, 652. doi: 10.3389/fneur.2019.00652

  • CrossRef
  • Google Scholar

• 107

  LinM. T.BealM. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature443, 787–795. doi: 10.1038/nature05292

  • CrossRef
  • Google Scholar

• 108

  LinC.-H.ChenC.-C.ChiangH.-L.LiouJ.-M.ChangC.-M.LuT.-P.et al. (2019). Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease. J. Neuroinflamm16, 129. doi: 10.1186/s12974-019-1528-y

  • CrossRef
  • Google Scholar

• 109

  LindvallO.KokaiaZ. (2009). Prospects of stem cell therapy for replacing dopamine neurons in Parkinson’s disease. Trends Pharmacol. Sci.30, 260–267. doi: 10.1016/j.tips.2009.03.001

  • CrossRef
  • Google Scholar

• 110

  LionnetA.Leclair-VisonneauL.NeunlistM.MurayamaS.TakaoM.AdlerC. H.et al. (2018). Does Parkinson’s disease start in the gut? Acta Neuropathol.135, 1–12. doi: 10.1007/s00401-017-1777-8

  • CrossRef
  • Google Scholar

• 111

  LonghenaF.FaustiniG.MissaleC.PizziM.SpanoP.BellucciA. (2017). The contribution of α-synuclein spreading to Parkinson’s disease synaptopathy. Neural Plast.2017, 1–15. doi: 10.1155/2017/5012129

  • CrossRef
  • Google Scholar

• 112

  LonghenaF.FaustiniG.SpillantiniM. G.BellucciA. (2019). Living in promiscuity: the multiple partners of alpha-synuclein at the synapse in physiology and pathology. Int. J. Mol. Sci.20, 141. doi: 10.3390/ijms20010141

  • CrossRef
  • Google Scholar

• 113

  LuczynskiP.Mcvey NeufeldK.-A.OriachC. S.ClarkeG.DinanT. G.CryanJ. F. (2016). Growing up in a bubble: using germ-free animals to assess the influence of the gut microbiota on brain and behavior. Int. J. Neuropsychopharmacol.19, 1–17. doi: 10.1093/ijnp/pyw020

  • CrossRef
  • Google Scholar

• 114

  MahmoudianDehkordiS.ArnoldM.NhoK.AhmadS.JiaW.XieG.et al. (2019). Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease—An emerging role for gut microbiome. Alzheimer’s Dementia15, 76–92. doi: 10.1016/j.jalz.2018.07.217

  • CrossRef
  • Google Scholar

• 115

  ManzoniC.LewisP. A. (2013). Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB J.27, 3424–3429. doi: 10.1096/fj.12-223842

  • CrossRef
  • Google Scholar

• 116

  MarquesE. P.WyseA. T. (2019). Creatine as a neuroprotector: an actor that can play many parts. Neurotoxic. Res.36, 1–13. doi: 10.1007/s12640-019-00053-7

  • CrossRef
  • Google Scholar

• 117

  MarshL. (2013). Depression and Parkinson’s disease: current knowledge. Curr. Neurol. Neurosci. Rep.13, 409. doi: 10.1007/s11910-013-0409-5

  • CrossRef
  • Google Scholar

• 118

  MasliahE.RockensteinE.AdameA.AlfordM.CrewsL.HashimotoM.et al. (2005). Effects of α-synuclein immunization in a mouse model of Parkinson’s disease. Neuron46, 857–868. doi: 10.1016/j.neuron.2005.05.010

  • CrossRef
  • Google Scholar

• 119

  MasliahE.RockensteinE.ManteM.CrewsL.SpencerB.AdameA.et al. (2011). Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One6, e19338. doi: 10.1371/journal.pone.0019338

  • CrossRef
  • Google Scholar

• 120

  MertsalmiT.AhoV.PereiraP.PaulinL.PekkonenE.AuvinenP.et al. (2017). More than constipation–bowel symptoms in Parkinson’s disease and their connection to gut microbiota. Eur. J. Neurol.24, 1375–1383. doi: 10.1111/ene.13398

  • CrossRef
  • Google Scholar

• 121

  MilberJ. M.NoorigianJ. V.MorleyJ. F.PetrovitchH.WhiteL.RossG. W.et al. (2012). Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology79, 2307–2314. doi: 10.1212/WNL.0b013e318278fe32

  • CrossRef
  • Google Scholar

• 122

  MinatoT.MaedaT.FujisawaY.TsujiH.NomotoK.OhnoK.et al. (2017). Progression of Parkinson’s disease is associated with gut dysbiosis: two-year follow-up study. PLoS One12, e0187307. doi: 10.1371/journal.pone.0187307

  • CrossRef
  • Google Scholar

• 123

  MishimaT.FujiokaS.YamaguchiY.HayashiY.OnozawaR.FukaeJ.et al. (2018). Role of anticholinergic medications in the treatment of Parkinson’s disease. Parkinsonism Related Disord.46, e85. doi: 10.1016/j.parkreldis.2017.11.296

  • CrossRef
  • Google Scholar

• 124

  MorrowS. A.RosehartH.SenerA.WelkB. (2018). Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis. J. Neurol. Sci.385, 39–44. doi: 10.1016/j.jns.2017.11.028

  • CrossRef
  • Google Scholar

• 125

  MulakA.BonazB. (2015). Brain-gut-microbiota axis in Parkinson’s disease. World J. Gastroenterol.: WJG21, 10609. doi: 10.3748/wjg.v21.i37.10609

  • CrossRef
  • Google Scholar

• 126

  NairA. T.RamachandranV.JogheeN. M.AntonyS.RamalingamG. (2018). Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson’s disease: a critical review. J. Neurogastroenterol. Motil.24, 30. doi: 10.5056/jnm17105

  • CrossRef
  • Google Scholar

• 127

  NishiwakiH.ItoM.IshidaT.HamaguchiT.MaedaT.KashiharaK.et al. (2020). Meta-Analysis of Gut Dysbiosis in Parkinson’s Disease. Mov. Disord.35, 1626–1635. doi: 10.1002/mds.28119

  • CrossRef
  • Google Scholar

• 128

  NishtalaP. S.SalahudeenM. S.HilmerS. N. (2016). Anticholinergics: theoretical and clinical overview. Expert Opin. Drug Saf.15, 753–768. doi: 10.1517/14740338.2016.1165664

  • CrossRef
  • Google Scholar

• 129

  NormileD. (2018). First-of-its-kind clinical trial will use reprogrammed adult stem cells to treat Parkinson’s. Science80. doi: 10.1126/science.aau9466

  • CrossRef
  • Google Scholar

• 130

  NussbaumR. L.EllisC. E. (2003). Alzheimer’s disease and Parkinson’s disease. N. Engl. J. Med.348, 1356–1364. doi: 10.1056/NEJM2003ra020003

  • CrossRef
  • Google Scholar

• 131

  OlanowC. W.WatkinsP. B. (2007). Tolcapone: an efficacy and safety review, (2007). Clin. Neuropharmacol.30, 287–294. doi: 10.1097/wnf.0b013e318038d2b6

  • CrossRef
  • Google Scholar

• 132

  OlanowC. W.WattsR. L.KollerW. C. (2001). An algorithm (decision tree) for the management of Parkinson’s disease, (2001)):: Treatment Guidelines. Neurology56, S1–S88. doi: 10.1212/WNL.56.suppl_5.S1

  • CrossRef
  • Google Scholar

• 133

  O’DonovanS. M.CrowleyE. K.BrownJ. R. M.O’sullivanO.O’learyO. F.TimmonsS.et al. (2020). Nigral overexpression of α-synuclein in a rat Parkinson’s disease model indicates alterations in the enteric nervous system and the gut microbiome. Neurogastroenterol. Motil.32, e13726. doi: 10.1111/nmo.13726

  • CrossRef
  • Google Scholar

• 134

  ÖzoğulF.KuleyE.ÖzoğulY.Özoğulİ. (2012). The function of lactic acid bacteria on biogenic amines production by food-borne pathogens in arginine decarboxylase broth. Food Sci. Technol. Res.18, 795–804. doi: 10.3136/fstr.18.795

  • CrossRef
  • Google Scholar

• 135

  ÖzoğulF. (2004). Production of biogenic amines by Morganella morganii, Klebsiella pneumoniae and Hafnia alvei using a rapid HPLC method. Eur. Food Res. Technol.219, 465–469. doi: 10.1007/s00217-004-0988-0

  • CrossRef
  • Google Scholar

• 136

  PahwaR.LyonsK. E. (2009). Levodopa-related wearing-off in Parkinson’s disease: identification and management. Curr. Med. Res. Opin.25, 841–849. doi: 10.1185/03007990902779319

  • CrossRef
  • Google Scholar

• 137

  ParasharA.UdayabanuM. (2017). Gut microbiota: Implications in Parkinson’s disease. Parkinsonism Related Disord.38, 1–7. doi: 10.1016/j.parkreldis.2017.02.002

  • CrossRef
  • Google Scholar

• 138

  ParkJ. H.LeeS. H.KimY.ParkS. W.ByeonG. H.JangJ. W.et al. (2020). Depressive symptoms are associated with worse cognitive prognosis in patients with newly diagnosed idiopathic Parkinson disease. Psychogeriatrics. doi: 10.1111/psyg.12601

  • CrossRef
  • Google Scholar

• 139

  ParkkinenL.PirttiläT.AlafuzoffI. (2008). Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. Acta Neuropathol.115, 399–407. doi: 10.1007/s00401-008-0346-6

  • CrossRef
  • Google Scholar

• 140

  ParmarM.GrealishS.HenchcliffeC. (2020). The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci.21, 1–13. doi: 10.1038/s41583-019-0257-7

  • CrossRef
  • Google Scholar

• 141

  PatelS.GarciaX.MohammadM. E.YuX. X.VlastarisK.O'DonnellK.et al. (2017). Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center. J Neurol Sci379, 308–311. doi: 10.1016/j.jns.2017.06.022

  • CrossRef
  • Google Scholar

• 142

  PiquetA. L.VenkiteswaranK.MarupudiN. I.BerkM.SubramanianT. (2012). The immunological challenges of cell transplantation for the treatment of Parkinson’s disease. Brain Res. Bull.88, 320–331. doi: 10.1016/j.brainresbull.2012.03.001

  • CrossRef
  • Google Scholar

• 143

  PoirierA.-A.AubéB.CôtéM.MorinN.Di PaoloT.SouletD. (2016). Gastrointestinal dysfunctions in Parkinson’s disease: symptoms and treatments. Parkinson’s Dis.2016, 1–23. doi: 10.1155/2016/6762528

  • CrossRef
  • Google Scholar

• 144

  PokusaevaK.JohnsonC.LukB.UribeG.FuY.OezguenN.et al. (2017). GABA-producing Bifidobacterium dentium modulates visceral sensitivity in the intestine. Neurogastroenterol. Motil.29, e12904. doi: 10.1111/nmo.12904

  • CrossRef
  • Google Scholar

• 145

  PuY.ChangL.QuY.WangS.ZhangK.HashimotoK. (2019). Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain. Aging (Albany NY)11, 6915. doi: 10.18632/aging.102221

  • CrossRef
  • Google Scholar

• 146

  QiaoC.-M.SunM.-F.JiaX.-B.ShiY.ZhangB.-P.ZhouZ.-L.et al. (2020). Sodium butyrate causes α-synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway. Exp. Cell Res.387, 111772. doi: 10.1016/j.yexcr.2019.111772

  • CrossRef
  • Google Scholar

• 147

  RecasensA.DehayB. (2014). Alpha-synuclein spreading in Parkinson’s disease. Front. Neuroanat.8, 159. doi: 10.3389/fnana.2014.00159

  • CrossRef
  • Google Scholar

• 148

  ReeveA.SimcoxE.TurnbullD. (2014). Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res. Rev.14, 19–30. doi: 10.1016/j.arr.2014.01.004

  • CrossRef
  • Google Scholar

• 149

  ReidG. (2019). Disentangling what we know about microbes and mental health. Front. Endocrinol.10, 81–87. doi: 10.3389/fendo.2019.00081

  • CrossRef
  • Google Scholar

• 150

  RepovšG.BaddeleyA. (2006). The multi-component model of working memory: Explorations in experimental cognitive psychology. Neuroscience139, 5–21. doi: 10.1016/j.neuroscience.2005.12.061

  • CrossRef
  • Google Scholar

• 151

  ReyN. L.SteinerJ. A.MaroofN.LukK. C.MadajZ.TrojanowskiJ. Q.et al. (2016). Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J. Exp. Med.213, 1759–1778. doi: 10.1084/jem.20160368

  • CrossRef
  • Google Scholar

• 152

  ReynoldsA. D.StoneD. K.HutterJ. A.BennerE. J.MosleyR. L.GendelmanH. E. (2010). Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J. Immunol.184, 2261–2271. doi: 10.4049/jimmunol.0901852

  • CrossRef
  • Google Scholar

• 153

  RiteI.MachadoA.CanoJ.VeneroJ. L. (2007). Blood–brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J. Neurochem.101, 1567–1582. doi: 10.1111/j.1471-4159.2007.04567.x

  • CrossRef
  • Google Scholar

• 154

  RogersG. B.KeatingD. J.YoungR. L.WongM. L.LicinioJ.WesselinghS. (2016). From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry21, 738–748. doi: 10.1038/mp.2016.50

  • CrossRef
  • Google Scholar

• 155

  SampsonT. R.DebeliusJ. W.ThronT.JanssenS.ShastriG. G.IlhanZ. E.et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell167, 1469–1480.e1412. doi: 10.1016/j.cell.2016.11.018

  • CrossRef
  • Google Scholar

• 156

  SarkarS. R.BanerjeeS. (2019). Gut microbiota in neurodegenerative disorders. J. Neuroimmunol.328, 98–104. doi: 10.1016/j.jneuroim.2019.01.004

  • CrossRef
  • Google Scholar

• 157

  SchapiraA. H.JennerP. (2011). Etiology and pathogenesis of Parkinson’s disease. Mov. Disord.26, 1049–1055. doi: 10.1002/mds.23732

  • CrossRef
  • Google Scholar

• 158

  ScheperjansF.AhoV.PereiraP. A.KoskinenK.PaulinL.PekkonenE.et al. (2015). Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov. Disord.30, 350–358. doi: 10.1002/mds.26069

  • CrossRef
  • Google Scholar

• 159

  SchlesingerI.KorczynA. D. (2016). Catechol-O-methyltransferase inhibitors in the management of Parkinson’s disease. Parkinson’s Disease: Curr. Future Ther. Clin. Trials76, 76–82. doi: 10.1017/CBO9781107284210.008

  • CrossRef
  • Google Scholar

• 160

  Schulz-SchaefferW. J. (2010). The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol.120, 131–143. doi: 10.1007/s00401-010-0711-0

  • CrossRef
  • Google Scholar

• 161

  SgrittaM.DoolingS. W.BuffingtonS. A.MominE. N.FrancisM. B.BrittonR. A.et al. (2019). Mechanisms underlying microbial-mediated changes in social behavior in mouse models of autism spectrum disorder. Neuron101, 246–259. e246. doi: 10.1016/j.neuron.2018.11.018

  • CrossRef
  • Google Scholar

• 162

  ShahM.DeebJ.FernandoM.NoyceA.VisentinE.FindleyL. J.et al. (2009). Abnormality of taste and smell in Parkinson’s disease. Parkinsonism Related Disord.15, 232–237. doi: 10.1016/j.parkreldis.2008.05.008

  • CrossRef
  • Google Scholar

• 163

  SheridanC.MartinS. J. (2010). Mitochondrial fission/fusion dynamics and apoptosis. Mitochondrion10, 640–648. doi: 10.1016/j.mito.2010.08.005

  • CrossRef
  • Google Scholar

• 164

  ShishovV.KirovskayaT.KudrinV.OleskinA. (2009). Amine neuromediators, their precursors, and oxidation products in the culture of Escherichia coli K-12. Appl. Biochem. Microbiol.45, 494–497. doi: 10.1134/S0003683809050068

  • CrossRef
  • Google Scholar

• 165

  SilvaT. B.BorgesF.SerrãoM. P.Soares-Da-SilvaP. (2020). Liver says no: the ongoing search for safe catechol O-methyltransferase inhibitors to replace tolcapone. Drug Discov. Today. doi: 10.1016/j.drudis.2020.07.015

  • CrossRef
  • Google Scholar

• 166

  SimrénM.BarbaraG.FlintH. J.SpiegelB. M.SpillerR. C.VannerS.et al. (2013). Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut62, 159–176. doi: 10.1136/gutjnl-2012-302167

  • CrossRef
  • Google Scholar

• 167

  SokolH.PigneurB.WatterlotL.LakhdariO.Bermúdez-HumaránL. G.GratadouxJ.-J.et al. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci.105, 16731–16736. doi: 10.1073/pnas.0804812105

  • CrossRef
  • Google Scholar

• 168

  SpillantiniM. G.CrowtherR. A.JakesR.HasegawaM.GoedertM. (1998). α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci.95, 6469–6473. doi: 10.1073/pnas.95.11.6469

  • CrossRef
  • Google Scholar

• 169

  SrivastavS.NeupaneS.BhurtelS.KatilaN.MaharjanS.ChoiH.et al. (2019). Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. J. Nutr. Biochem.69, 73–86. doi: 10.1016/j.jnutbio.2019.03.021

  • CrossRef
  • Google Scholar

• 170

  StillingR. M.DinanT. G.CryanJ. F. (2014). Microbial genes, brain & behaviour–epigenetic regulation of the gut–brain axis. Genes Brain Behav.13, 69–86. doi: 10.1111/gbb.12109

  • CrossRef
  • Google Scholar

• 171

  StrandwitzP.KimK. H.TerekhovaD.LiuJ. K.SharmaA.LeveringJ.et al. (2019). GABA-modulating bacteria of the human gut microbiota. Nat. Microbiol.4, 396–403. doi: 10.1038/s41564-018-0307-3

  • CrossRef
  • Google Scholar

• 172

  SudoN.ChidaY.AibaY.SonodaJ.OyamaN.YuX. N.et al. (2004). Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. J. Physiol.558, 263–275. doi: 10.1113/jphysiol.2004.063388

  • CrossRef
  • Google Scholar

• 173

  SuenD.-F.NorrisK. L.YouleR. J. (2008). Mitochondrial dynamics and apoptosis. Genes Dev.22, 1577–1590. doi: 10.1101/gad.1658508

  • CrossRef
  • Google Scholar

• 174

  SulzerD. (2007). Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci.30, 244–250. doi: 10.1016/j.tins.2007.03.009

  • CrossRef
  • Google Scholar

• 175

  SunM.-F.ZhuY.-L.ZhouZ.-L.JiaX.-B.XuY.-D.YangQ.et al. (2018). Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav. Immun.70, 48–60. doi: 10.1016/j.bbi.2018.02.005

  • CrossRef
  • Google Scholar

• 176

  SurwaseS. N.JadhavJ. P. (2011). Bioconversion of L-tyrosine to L-DOPA by a novel bacterium Bacillus sp. JPJ. Amino Acids41, 495–506. doi: 10.1007/s00726-010-0768-z

  • CrossRef
  • Google Scholar

• 177

  SzökőÉ.TábiT.RiedererP.VécseiL.MagyarK. (2018). Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease. J. Neural Transm.125, 1735–1749. doi: 10.1007/s00702-018-1853-9

  • CrossRef
  • Google Scholar

• 178

  TabaP. (2017). “Toxic-induced parkinsonism,” in Movement Disorders Curricula. (Springer Vienna: Springer), 225–232.

  • Google Scholar

• 179

  TabakmanR.LechtS.LazaroviciP. (2004). Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson’s disease? Bioessays26, 80–90. doi: 10.1002/bies.10378

  • CrossRef
  • Google Scholar

• 180

  TanakaM.KimY. M.LeeG.JunnE.IwatsuboT.MouradianM. M. (2004). Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem.279, 4625–4631. doi: 10.1074/jbc.M310994200

  • CrossRef
  • Google Scholar

• 181

  ThomasS.IzardJ.WalshE.BatichK.ChongsathidkietP.ClarkeG.et al. (2017). The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists. Cancer Res.77, 1783–1812. doi: 10.1158/0008-5472.CAN-16-2929

  • CrossRef
  • Google Scholar

• 182

  TranT. N.VoT. N.FreiK.TruongD. D. (2018). Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J. Neural Transm.125, 1109–1117. doi: 10.1007/s00702-018-1900-6

  • CrossRef
  • Google Scholar

• 183

  TsavkelovaE.BotvinkoI.KudrinV.OleskinA. (2000). Detection of neurotransmitter amines in microorganisms with the use of high-performance liquid chromatography. Doklady Biochem.: Proc. Acad. Sci. USSR Biochem. Section372, 115. doi: 10.1038/mp.2016.50

  • CrossRef
  • Google Scholar

• 184

  TsuangD.LeverenzJ. B.LopezO. L.HamiltonR. L.BennettD. A.SchneiderJ. A.et al. (2013). APOE ϵ4 increases risk for dementia in pure synucleinopathies. JAMA Neurol.70, 223–228. doi: 10.1001/jamaneurol.2013.600

  • CrossRef
  • Google Scholar

• 185

  TufekciK. U.GencS.GencK. (2011). The endotoxin-induced neuroinflammation model of Parkinson’s disease. Parkinson’s Dis.2011. doi: 10.4061/2011/487450

  • CrossRef
  • Google Scholar

• 186

  UngerM. M.SpiegelJ.DillmannK.-U.GrundmannD.PhilippeitH.BürmannJ.et al. (2016). Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Related Disord.32, 66–72. doi: 10.1016/j.parkreldis.2016.08.019

  • CrossRef
  • Google Scholar

• 187

  Valdez-MoralesE. E.OveringtonJ.Guerrero-AlbaR.Ochoa-CortesF.IbeakanmaC. O.SpreadburyI.et al. (2013). Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. Am. J. Gastroenterol.108, 1634–1643. doi: 10.1038/ajg.2013.241

  • CrossRef
  • Google Scholar

• 188

  van KesselS. P.FryeA. K.El-GendyA. O.CastejonM.KeshavarzianA.Van DijkG.et al. (2019). Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat. Commun.10, 1–11. doi: 10.1038/s41467-019-08294-y

  • CrossRef
  • Google Scholar

• 189

  VaughanR. A.FosterJ. D. (2013). Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol. Sci.34, 489–496. doi: 10.1016/j.tips.2013.07.005

  • CrossRef
  • Google Scholar

• 190

  VilaM.PrzedborskiS. (2004). Genetic clues to the pathogenesis of Parkinson’s disease. Nat. Med.10, S58–S62. doi: 10.1038/nm1068

  • CrossRef
  • Google Scholar

• 191

  VincentA. D.WangX.-Y.ParsonsS. P.KhanW. I.HuizingaJ. D. (2018). Abnormal absorptive colonic motor activity in germ-free mice is rectified by butyrate, an effect possibly mediated by mucosal serotonin. Am. J. Physiology-Gastrointestinal Liver Physiol.315, G896–G907. doi: 10.1152/ajpgi.00237.2017

  • CrossRef
  • Google Scholar

• 192

  Volpicelli-DaleyL. A.GambleK. L.SchultheissC. E.RiddleD. M.WestA. B.LeeV. M.-Y. (2014). Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes. Mol. Biol. Cell25, 4010–4023. doi: 10.1091/mbc.e14-02-0741

  • CrossRef
  • Google Scholar

• 193

  WallenZ. D.AppahM.DeanM. N.SeslerC. L.FactorS. A.MolhoE.et al. (2020). Characterizing dysbiosis of gut microbiome in PD: Evidence for overabundance of opportunistic pathogens. NPJ Parkinson’s Dis.6, 1–12. doi: 10.1101/2020.01.13.905166

  • CrossRef
  • Google Scholar

• 194

  WangL.DasU.ScottD. A.TangY.McleanP. J.RoyS. (2014). α-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol.24, 2319–2326. doi: 10.1016/j.cub.2014.08.027

  • CrossRef
  • Google Scholar

• 195

  WangP.-S.YehC.-L.LuC.-F.WuH.-M.SoongB.-W.WuY.-T. (2017). The involvement of supratentorial white matter in multiple system atrophy: a diffusion tensor imaging tractography study. Acta Neurol. Belgica117, 213–220. doi: 10.1007/s13760-016-0724-0

  • CrossRef
  • Google Scholar

• 196

  WangH.LiuX.TanC.ZhouW.JiangJ.PengW.et al. (2020). Bacterial, viral, and fungal infection-related risk of Parkinson’s disease: Meta-analysis of cohort and case–control studies. Brain Behav.10, e01549. doi: 10.1002/brb3.1549

  • CrossRef
  • Google Scholar

• 197

  WolfE.SeppiK.KatzenschlagerR.HochschornerG.RansmayrG.SchwingenschuhP.et al. (2010). Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov. Disord.25, 1357–1363. doi: 10.1002/mds.23034

  • CrossRef
  • Google Scholar

• 198

  WooM.HakemR.FurlongerC.HakemA.DuncanG. S.SasakiT.et al. (2003). Caspase-3 regulates cell cycle in B cells: a consequence of substrate specificity. Nat. Immunol.4, 1016–1022. doi: 10.1038/ni976

  • CrossRef
  • Google Scholar

• 199

  XiaoY.LuoM.LuoH.WangJ. (2014). Creatine for Parkinson’s disease. Cochrane Database Syst. Rev.CD009646. doi: 10.1002/14651858.CD009646.pub2

  • CrossRef
  • Google Scholar

• 200

  YamadaM.IwatsuboT.MizunoY.MochizukiH. (2004). Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson’s disease. J. Neurochem.91, 451–461. doi: 10.1111/j.1471-4159.2004.02728.x

  • CrossRef
  • Google Scholar

• 201

  YanoJ. M.YuK.DonaldsonG. P.ShastriG. G.AnnP.MaL.et al. (2015). Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell161, 264–276. doi: 10.1016/j.cell.2015.02.047

  • CrossRef
  • Google Scholar

• 202

  YuX. X.FernandezH. H. (2017). Dopamine agonist withdrawal syndrome: a comprehensive review. J. Neurol. Sci.374, 53–55. doi: 10.1016/j.jns.2016.12.070

  • CrossRef
  • Google Scholar

• 203

  YuQ.-J.YuS.-Y.ZuoL.-J.LianT.-H.HuY.WangR.-D.et al. (2018). Parkinson disease with constipation: clinical features and relevant factors. Sci. Rep.8, 1–9. doi: 10.1038/s41598-017-16790-8

  • CrossRef
  • Google Scholar

• 204

  ZhangF.LuoW.ShiY.FanZ.JiG. (2012). Should we standardize the 1,700-year-old fecal microbiota transplantation? Am. J. Gastroenterol.107, 1755. doi: 10.1038/ajg.2012.251

  • CrossRef
  • Google Scholar

• 205

  ZoetendalE. G.RaesJ.Van Den BogertB.ArumugamM.BooijinkC. C.TroostF. J.et al. (2012). The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME J.6, 1415–1426. doi: 10.1038/ismej.2011.212

  • CrossRef
  • Google Scholar